Anti-Mouse ICOSL/CD275 Antibody (HK5.3)

Cat. No.: HY-P990123 Purity: 98.59%: Data Sheet
COA

SDS

FAQs
Technical Support

Anti-Mouse ICOSL/CD275 Antibody (HK5.3) is an anti-mouse ICOSL/CD275 IgG2a monoclonal antibody. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can inhibit the adhesion between T cells and endothelial cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can reduce the expansion of tissue resident (TR) Treg cells. Anti-Mouse ICOSL/CD275 Antibody (HK5.3) can be used for researches on inflammation and infection conditions such as influenza virus infection and arthritis.

For research use only. We do not sell to patients.

Anti-Mouse ICOSL/CD275 Antibody (HK5.3) Chemical Structure

Size	Stock	Quantity
1 mg	In-stock	Estimated Time of Arrival: December 31
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Anti-Mouse ICOSL/CD275 Antibody (HK5.3) Featured Recommendations:

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Isotype

Rat IgG2a kappa

Recommend Isotype Controls

Rat IgG2a kappa, Isotype Control

Species Reactivity

Mouse

IC₅₀ & Target

ICOSL/CD275

In Vitro

Anti-Mouse ICOSL/CD275 Antibody (HK5.3) (15 μg/mL, 30 min) significantly reduces adhesion of Th1 and Th17 cells to primary mouse brain microvascular endothelial cells (pMBMECs)^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Anti-Mouse ICOSL/CD275 Antibody (HK5.3) (100 μg, i.p., on day 0, 3, 6, and 9 after hydrodynamic tail vein (HDTV) injection) significantly reduces the clearance of aging liver cells in wild-type C57BL/6 mice with a liver cell aging model^[1].
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) (250-500 μg, i.v., on day -1, 1 and 3) significantly reduces the expansion of TR Treg cells in C57BL/6 mice with an influenza virus infection model^[3].
Anti-Mouse ICOSL/CD275 Antibody (HK5.3) (15 mg/kg, i.p., on day 19, 21, 23, and 25) significantly delays the onset of arthritis in female DBA1 mice with a bovine collagen-induced arthritis model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HDTV injected wild-type C57Bl/6 mice^[1]
Dosage:	100 μg
Administration:	Intraperitoneal injection (i.p.), on day 0, 3, 6, and 9 after HDTV injection
Result:	Significantly increased the number of liver cells.

Animal Model:	200 PFU H1N1 virus primary infected and 2×10⁴H3N2 virus followed infected C57BL/6 mice (6-15 weeks)^[3]
Dosage:	500 μg for first-dose, 250 μg for subsequent doses
Administration:	Intravenous injection (i.v.), on day -1, 1 and 3
Result:	Significantly reduced the expansion of TR Treg cells (especially IL-10⁺ subpopulation), but did not affect other T cell subpopulations. Had no significant effect on PD-1 expression, but reduced the survival rate of TR Treg cells. Reduced the level of IL-10.

Animal Model:	Bovine collagen injected female DBA1 mice^[4]
Dosage:	15 mg/kg
Administration:	Intraperitoneal injection (i.p.), on day 19, 21, 23, and 25
Result:	Significantly delayed the onset of arthritis. Reduced inflammation score. Reduced joint damage, cartilage injury, and inflammatory cell infiltration.

Gene ID

50723 [NCBI]

Accession

Q9JHJ8-1

Molecular Weight

150 kDa

Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Anti-Mouse ICOSL/CD275 Antibody (HK5.3)]

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

Purity & Documentation

Purity: 98.59%

Select Batch:

Data Sheet (262 KB) SDS (251 KB)

COA (232 KB) SEC-HPLC (322 KB)

Inhibitory Antibodies User Guide (602 KB)

References

[1]. Yin K, et al. Senescence-induced endothelial phenotypes underpin immune-mediated senescence surveillance. Genes Dev. 2022 May 1;36(9-10):533-549. [Content Brief]

[2]. Johann L, et al. A20 regulates lymphocyte adhesion in murine neuroinflammation by restricting endothelial ICOSL expression in the CNS. J Clin Invest. 2023 Dec 15;133(24):e168314. [Content Brief]

[3]. McGee MC, et al. PD-1 and ICOS counter-regulate tissue resident regulatory T cell development and IL-10 production during flu. Front Immunol. 2022 Sep 8;13:984476. [Content Brief]

[4]. O'Dwyer R, et al. Anti-ICOSL New Antigen Receptor Domains Inhibit T Cell Proliferation and Reduce the Development of Inflammation in the Collagen-Induced Mouse Model of Rheumatoid Arthritis. J Immunol Res. 2018 Oct 17;2018:4089459. [Content Brief]

Anti-Mouse ICOSL/CD275 Antibody (HK5.3) Related Classifications

Inflammation/Immunology Infection

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass		Concentration		Volume		Molecular Weight *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)	×	Volume _(start)	=	Concentration _(final)	×	Volume _(final)
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Anti-Mouse ICOSL/CD275 Antibody (HK5.3)Transmembrane GlycoproteinInfluenza VirusICOSL/CD275T cellsTregH1N1H3N2arthritisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *